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The Journal’s April supplement included many in-
formative articles about the Lives Saved Tool (LiST),
such as how modelling and calculations are built into
the tool, actual calculations of effect sizes in the soft-
ware and recent applications of various LiST scen-
arios. We understand that LiST was developed to be
used as part of a package of tools for programme
managers or ministry of health personnel for plan-
ning, helping prioritize investments and evaluating
existing programmes.
Because of the potential power of this tool, how
it gets used becomes a critical issue. Presently,
we understand that LiST is primarily being used to
advocate for new interventions or those with relative-
ly low coverage. Its focus is on future marginal mor-
tality gains. But the tool also has the capability to
convey important information, not highlighted in
the supplement, relating to more historically estab-
lished interventions that typically show higher
coverage—such as immunization and vitamin A.
Past mortality reduction gains must not be taken for
granted and indeed cannot be maintained without
continued investments. The tool’s versatility, if fully
exercised, could help users look at the bigger public
health picture, assessing both future marginal mortal-
ity gains (lives saved) and past mortality reduction
gains (by showing lives lost if gains are not
maintained).
Chopra et al.
1 note that ‘certain interventions for
which coverage is already high will not result in
many lives saved and this discrepancy may be mis-
understood: for example, immunization coverage is
high in South Africa so very few lives would be
saved by increasing from over 90% to our target of
95% coverage. However, if investment stopped and
coverage fell, mortality would rise. This effect can
also be modelled in LiST to ensure that misunder-
standings do not arise.’
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Figure 1 (a) Estimated additional child ‘Lives saved’ each year by increasing DTP3 coverage from 97% to 100%;
(b) Estimated child ‘Lives lost’ each year attributable to stopping all DTP3 vaccination (97% to 0%)
LETTERS TO THE EDITOR 519In order to use the full power of the tool—and to
avoid the misunderstanding highlighted by Chopra
et al.
1—LiST should not only be used to capture
‘gains’ (lives saved) but also possible ‘losses’ (lives
lost) as well. Capturing losses illustrates the import-
ance of maintaining a system (e.g. immunization) or
continuing life-saving household/family behaviours
(e.g. exclusive breastfeeding, as countries may
experience widespread behaviour changes with
urbanization). Expressing ‘lives lost’ will allow users
to also better understand the importance of continu-
ing to invest in mature, population-based preventive
interventions with high coverage.
To illustrate the ‘lives lost’ potential of the tool, we
have run LiST first as is normally done (left) and then
in the opposite direction (right), using South Africa as
an example with coverage (based on South Africa’s
reported coverage to illustrate the point in Chopra
et al.) for the third dose of diphtheria–tetanus–
pertussis (DTP) coverage (Figure 1a and b).
Running LiST in the opposite direction gives users
an idea of the lives already being saved by ‘successful’
interventions—and highlights the importance of con-
tinuing to invest in these interventions, to maintain
as well as further increase their coverage. When run-
ning LiST in the opposite direction, users should
understand that the tool uses a proportional
cause-specific (not intervention-focused) mortality
calculation. The calculation first takes into account
preventive measures (and assigns a protective factor
in the formula), and then considers curative meas-
ures. When coverage of preventive interventions is
reduced (e.g. running LiST in the opposite direction
for DTP3), greater weight is placed on the potential
impact of curative interventions—which will then
diminish the effect on estimates attributable to ‘lives
lost’.
Without thorough guidance about how to modify or
use the tool, so that a typical user can model the
number of lives being saved with continued successful
use of an intervention at baseline (by showing ‘lives
lost’) plus additional lives saved if coverage increases,
we fear that LiST will be viewed by decision makers
as ‘turn-key’. It could also run the risk of being used
as a stand-alone tool rather than as part of a series of
planning tools as apparently intended.
It is important for users to look at the comprehen-
sive effects of prioritization with the tool—for new
and low-coverage interventions that need to be
strengthened and high-coverage interventions that
need to be maintained and further strengthened.
Furthermore, LiST does not assess health system con-
straints, thus giving no idea of the cost implications
of increased coverage, that is, how credible a target is
given the weaknesses of the current health system.
Similarly, LiST does not distinguish between achiev-
ing mortality reductions with relatively cost-effective
preventive interventions such as immunization or
vitamin A supplementation vs reliance on more
costly curative interventions.
We encourage the LiST authors to incorporate clear-
er instructions into the tool so that the typical user
can operate LiST at its full power—to express lives
saved as well as lives lost if gains in higher coverage
interventions are not maintained.
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Robert Steinglass et al.
1 highlight that ‘how’ the Lives
Saved Tool (LiST) gets used is a critical issue and we
fully agree. LiST is to be used to assess the potential
mortality impact of improving the coverage of interven-
tions whether they are long-standing or new ones. They
are not correct in saying that it is primarily being used
to advocate for new or low-coverage interventions. It
estimates the additional effects of this increased cover-
age giving first priority to preventive interventions,
such as immunizations. What Steinglass et al. are call-
ing ‘advocacy’ we understand as promoting
evidence-based decision making for planning the ap-
propriate expansion of interventions. Of course, inter-
ventions that are already at high coverage will have
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